Sensydia Completes $6M+ Funding Round
2026-10-13
Tweet
LOS ANGELES, CA, Sensydia, a clinical-stage medical technology company advancing non-invasive cardiac assessment, today announced an oversubscribed initial closing of $6+ million in its latest financing.
The round was led by Colle Capital Partners with substantial support from Orlando Health Ventures. Proceeds will carry Sensydia's Cardiac Performance System (CPS™) through its ACOUSTIC'1 study to FDA authorization while supporting commercial launch preparation.
Sensydia is developing the Cardiac Performance System (CPS™), a non-invasive platform designed to give clinicians rapid, safe, and accurate assessments of hemodynamic function in the office or clinic, to help them better diagnose and manage heart failure and pulmonary hypertension and improve patient outcomes. CPS has received FDA Breakthrough Device designation. The company's regulatory history includes FDA 510(k) clearance in 2018 for an algorithm for non-invasive measurement of ejection fraction.
Sensydia is developing the Cardiac Performance System (CPS™), a non-invasive platform designed to give clinicians rapid, safe, and accurate assessments of hemodynamic function in the office or clinic, to help them better diagnose and manage heart failure and pulmonary hypertension and improve patient outcomes. CPS has received FDA Breakthrough Device designation. The company's regulatory history includes FDA 510(k) clearance in 2018 for an algorithm for non-invasive measurement of ejection fraction.
(c) by Massinvestor, Inc. For contact info, please check out our about page.
>> Click here for in-depth research on 9,000+ startups and 5,000+ VC investors
